JP2013142059A - 腎細胞がん治療剤 - Google Patents
腎細胞がん治療剤 Download PDFInfo
- Publication number
- JP2013142059A JP2013142059A JP2012001595A JP2012001595A JP2013142059A JP 2013142059 A JP2013142059 A JP 2013142059A JP 2012001595 A JP2012001595 A JP 2012001595A JP 2012001595 A JP2012001595 A JP 2012001595A JP 2013142059 A JP2013142059 A JP 2013142059A
- Authority
- JP
- Japan
- Prior art keywords
- renal cell
- cell cancer
- group
- therapeutic agent
- cell carcinoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000006265 Renal cell carcinoma Diseases 0.000 title claims abstract description 41
- 208000015347 renal cell adenocarcinoma Diseases 0.000 title claims abstract description 17
- 229940043355 kinase inhibitor Drugs 0.000 claims abstract description 22
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims abstract description 22
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims abstract description 20
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229960003787 sorafenib Drugs 0.000 claims abstract description 20
- 229960002751 imiquimod Drugs 0.000 claims abstract description 19
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims abstract description 9
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims abstract description 8
- 229960001796 sunitinib Drugs 0.000 claims abstract description 8
- SPMVMDHWKHCIDT-UHFFFAOYSA-N 1-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-3-(5-methyl-3-isoxazolyl)urea Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC=1C=C(C)ON=1 SPMVMDHWKHCIDT-UHFFFAOYSA-N 0.000 claims abstract description 7
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims abstract description 6
- 229960003005 axitinib Drugs 0.000 claims abstract description 6
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims abstract description 6
- 229960002412 cediranib Drugs 0.000 claims abstract description 6
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960000639 pazopanib Drugs 0.000 claims abstract description 6
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960000940 tivozanib Drugs 0.000 claims abstract description 6
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims abstract description 5
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims abstract description 5
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims abstract description 5
- 229960001433 erlotinib Drugs 0.000 claims abstract description 5
- 229960002584 gefitinib Drugs 0.000 claims abstract description 5
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims abstract description 5
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229960002411 imatinib Drugs 0.000 claims abstract description 5
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229950010550 resiquimod Drugs 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims description 17
- 229940124597 therapeutic agent Drugs 0.000 claims description 15
- -1 dobitinib Chemical compound 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 abstract description 5
- 239000003795 chemical substances by application Substances 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- ZXBCLVSLRUWISJ-UHFFFAOYSA-N 2-methyl-1-(2-methylpropyl)imidazo[4,5-c][1,5]naphthyridin-4-amine Chemical compound C1=CC=NC2=C3N(CC(C)C)C(C)=NC3=C(N)N=C21 ZXBCLVSLRUWISJ-UHFFFAOYSA-N 0.000 abstract description 2
- 238000002512 chemotherapy Methods 0.000 abstract description 2
- KCOYQXZDFIIGCY-CZIZESTLSA-N (3e)-4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1,3-dihydrobenzimidazol-2-ylidene]quinolin-2-one Chemical compound C1CN(C)CCN1C1=CC=C(N\C(N2)=C/3C(=C4C(F)=CC=CC4=NC\3=O)N)C2=C1 KCOYQXZDFIIGCY-CZIZESTLSA-N 0.000 abstract 1
- 229950005778 dovitinib Drugs 0.000 abstract 1
- 229950008380 sotirimod Drugs 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- LKZVJKCSPGCLCH-UHFFFAOYSA-N 4,5-dihydro-1h-imidazole;quinoline Chemical class C1CN=CN1.N1=CC=CC2=CC=CC=C21 LKZVJKCSPGCLCH-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101100342473 Drosophila melanogaster Raf gene Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 101100523543 Rattus norvegicus Raf1 gene Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 101100523549 Xenopus laevis raf1 gene Proteins 0.000 description 1
- 101150037250 Zhx2 gene Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- PIQCTGMSNWUMAF-UHFFFAOYSA-N chembl522892 Chemical compound C1CN(C)CCN1C1=CC=C(NC(=N2)C=3C(NC4=CC=CC(F)=C4C=3N)=O)C2=C1 PIQCTGMSNWUMAF-UHFFFAOYSA-N 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 208000029691 metastatic malignant neoplasm in the lymph nodes Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- DRYRBWIFRVMRPV-UHFFFAOYSA-N quinazolin-4-amine Chemical compound C1=CC=C2C(N)=NC=NC2=C1 DRYRBWIFRVMRPV-UHFFFAOYSA-N 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
【解決手段】本発明に係る腎細胞がん治療剤は、ソラフェニブ、スニチニブ、アキシチニブ、パゾパニブ、セディラニブ、ティボザニブ、ドビチニブ、イマチニブ、ゲフィチニブ、エルロチニブおよびそれらの塩からなる群から選択される1以上のキナーゼ阻害薬と、イミキモド、レシキモド、ソチリモドおよびそれらの塩からなる群から選択される1以上のイミダゾリキノリン誘導体とを有効成分とすることを特徴とする。
【選択図】なし
Description
スニチニブ:N−[2−(ジエチルアミノ)エチル]−5−[(Z)−(5−フルオロ−2−オキソ−1,2−ジヒドロ−3H−インドール−3−イリデン)メチル]−2,4−ジメチル−1H−ピロール−3−カルボキシアミド
アキシチニブ:N−メチル−2−[[3−[(E)−2−(2−ピリジル)エテニル]−1H−インダゾール−6−イル]チオ]ベンズアミド
パゾパニブ:5−[[4−[(2,3−ジメチル−2H−インダゾール−6−イル)メチルアミノ]−2−ピリミジニル]アミノ]−2−メチルベンゾスルホンアミド
セディラニブ:4−[(4−フルオロ−2−メチル−1H−インドール−5−イル)オキシ]−6−メトキシ−7−[3−(ピロリジン−1−イル)プロポキシ]キナゾリン
ティボザニブ:1−{2−クロロ−4−[(6,7−ジメトキシキノリン−4−イル)オキシ]フェニル}−3−(5−メチルイソキサゾール−3−イル)ウレア
ドビチニブ:4−アミノ−5−フルオロ−3−[5−(4−メチルピペラジノ)−3H−ベンゾイミダゾール−2−イル]キノリン−2(1H)−オン
イマチニブ:4−(4−メチルピペラジン−1−イルメチル)−N−[4−メチル−3−(4−ピリジン−3−イルピリミジン−2−イルアミノ)フェニル]ベンズアミド
ゲフィチニブ:N−(3−クロロ−4−フルオロフェニル)−7−メトキシ−6−[3−(モルホリン−4−イル)プロポキシ]キナゾリン−4−アミン
エルロチニブ:N−(3−エチニルフェニル)−6,7−ビス(2−メトキシエトキシ)−4−キナゾリンアミン
レシキモド:α,α−ジメチル−4−アミノ−2−(エトキシメチル)−1H−イミダゾ[4 ,5−c]キノリン−1−エタノール
ソチリモド:2−メチル−1−(2−メチルプロピル)−1H−イミダゾ[4,5−c][1,5]ナフチリジン−4−アミン
5週齢のBALB/c系雌性マウス(体重:約25g)40匹を以下の実験に用いた。マウスに48mg/kgのネンブタールを腹腔内投与することにより麻酔し、除毛クリームにて背部を除毛した。106個のマウス腎細胞がん株RENCA細胞を、除毛した背部の皮下に異所移植した。移植後5日後に、マウスを無作為に1)コントロール群、2)ソラフェニブ単独投与群、3)イミキモド単独投与群、4)ソラフェニブ+イミキモド併用投与群の各群10匹の4群に分けた。
Claims (6)
- ソラフェニブ、スニチニブ、アキシチニブ、パゾパニブ、セディラニブ、ティボザニブ、ドビチニブ、イマチニブ、ゲフィチニブ、エルロチニブおよびそれらの塩からなる群から選択される1以上のキナーゼ阻害薬と、イミキモド、レシキモド、ソチリモドおよびそれらの塩からなる群から選択される1以上のイミダゾリキノリン誘導体とを有効成分とすることを特徴とする腎細胞がん治療剤。
- 腎細胞がんが遠隔転移したものである請求項1に記載の腎細胞がん治療剤。
- イミダゾリキノリン誘導体が経皮投与されるものである請求項1または2に記載の腎細胞がん治療剤。
- キナーゼ阻害薬が経口投与されるものである請求項1〜3のいずれかに記載の腎細胞がん治療剤。
- キナーゼ阻害薬がソラフェニブまたはその塩である請求項1〜4のいずれかに記載の腎細胞がん治療剤。
- イミダゾリキノリン誘導体がイミキモドである請求項1〜5のいずれかに記載の腎細胞がん治療剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012001595A JP5945863B2 (ja) | 2012-01-06 | 2012-01-06 | 腎細胞がん治療剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012001595A JP5945863B2 (ja) | 2012-01-06 | 2012-01-06 | 腎細胞がん治療剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013142059A true JP2013142059A (ja) | 2013-07-22 |
JP5945863B2 JP5945863B2 (ja) | 2016-07-05 |
Family
ID=49038830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012001595A Active JP5945863B2 (ja) | 2012-01-06 | 2012-01-06 | 腎細胞がん治療剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5945863B2 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017061445A (ja) * | 2015-07-31 | 2017-03-30 | レ ラボラトワール セルヴィエ | 3−[(3−{[4−(4−モルホリニルメチル)−1h−ピロール−2−イル]メチレン}−2−オキソ−2,3−ジヒドロ−1h−インドール−5−イル)メチル]−1,3−チアゾリジン−2,4−ジオンとegfrチロシンキナーゼ阻害剤との新しい併用 |
CN111658645A (zh) * | 2019-03-07 | 2020-09-15 | 天津市肿瘤医院 | R848或r848与索拉非尼联合用于治疗癌症的药物组合物和用途 |
KR20230051845A (ko) * | 2021-10-12 | 2023-04-19 | 가톨릭대학교 산학협력단 | 니클로스아마이드 및 수니티닙을 포함하는 신장암 예방 또는 치료용 약학적 조성물 |
-
2012
- 2012-01-06 JP JP2012001595A patent/JP5945863B2/ja active Active
Non-Patent Citations (5)
Title |
---|
JPN6015038690; 武内 在雄他: 'APP-001-AM 腎癌において抗腫瘍効果を示すソラフェニブ、インターフェロンalpha併用療法の作用機序' 日本泌尿器科学会雑誌 Vol.100, No.2, 2009, p.103(125) * |
JPN6015038691; 三浦 宏之他: '5%イミキモドクリームによる転移性腎細胞癌の治療' 日本皮膚科学会雑誌 第120巻、第3号, 2010, P34-9 * |
JPN6015038693; Takeuchi A, et al.: The journal of urology Vol.184, 2010, p.2549-2556 * |
JPN6015038694; 津田 敏彦他: 日薬理誌 Vol.132, 2008, p.55-63 * |
JPN6015038696; Sidky YA, et al.: Cancer Research Vol.52, 1992, p.3528-3533 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017061445A (ja) * | 2015-07-31 | 2017-03-30 | レ ラボラトワール セルヴィエ | 3−[(3−{[4−(4−モルホリニルメチル)−1h−ピロール−2−イル]メチレン}−2−オキソ−2,3−ジヒドロ−1h−インドール−5−イル)メチル]−1,3−チアゾリジン−2,4−ジオンとegfrチロシンキナーゼ阻害剤との新しい併用 |
CN111658645A (zh) * | 2019-03-07 | 2020-09-15 | 天津市肿瘤医院 | R848或r848与索拉非尼联合用于治疗癌症的药物组合物和用途 |
KR20230051845A (ko) * | 2021-10-12 | 2023-04-19 | 가톨릭대학교 산학협력단 | 니클로스아마이드 및 수니티닙을 포함하는 신장암 예방 또는 치료용 약학적 조성물 |
KR102595271B1 (ko) | 2021-10-12 | 2023-10-26 | 가톨릭대학교 산학협력단 | 니클로스아마이드 및 수니티닙을 포함하는 신장암 예방 또는 치료용 약학적 조성물 |
Also Published As
Publication number | Publication date |
---|---|
JP5945863B2 (ja) | 2016-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022058398A (ja) | Braf-v600関連疾患の治療に使用するためのplx-8394またはplx-7904 | |
RU2708247C2 (ru) | Соединение для лечения рака | |
IL270224B1 (en) | Combination therapy using trametinib and a defined RAF inhibitor | |
JP2011527703A (ja) | (a)ホスホイノシタイド3−キナーゼ阻害剤および(b)Ras/Raf/Mek経路のモジュレーターの配合物 | |
JP2007501238A (ja) | 癌の治療および阻害のための上皮増殖因子受容体キナーゼ阻害剤と細胞障害性物質との組み合わせの使用 | |
JP6768682B2 (ja) | メラノーマの処置に使用するためのアピリモド | |
JP2008536847A (ja) | ゲフィニチブ耐性患者における上皮増殖因子レセプター(egfr)キナーゼインヒビターの使用 | |
TW201217361A (en) | Method of treating abnormal cell growth | |
US20210220372A1 (en) | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof | |
US20210040050A1 (en) | Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof | |
CN105611928A (zh) | Pim激酶抑制剂组合 | |
AU2012257833A1 (en) | Method for treatment of solid malignancies including advanced or metastatic solid malignancies | |
JP5945863B2 (ja) | 腎細胞がん治療剤 | |
AU2017235346B2 (en) | Combination therapy for proliferative diseases | |
WO2016193955A1 (en) | Combinations of kinase inhibitors for treating colorectal cancer | |
JP2021523190A (ja) | 腺様嚢胞癌を治療するためのビスフルオロアルキル−1,4−ベンゾジアゼピノン化合物を含む組成物 | |
JP2021503457A5 (ja) | ||
EP2211849A2 (en) | Dexanabinol with inhibitors of braf or mek for the treatment of melanoma | |
JP2019519573A (ja) | がんを処置するための方法 | |
EP3668506B1 (en) | Enhancement of cancer treatment efficiency via the sphingosine-1-phosphate pathway | |
JP2022549272A (ja) | Egfr阻害剤とcdk4/6阻害剤の組み合わせを用いたegfr変異に関連する癌の治療 | |
TW201711686A (zh) | 3-[(3-{[4-(4-嗎啉基甲基)-1h-吡咯-2-基]亞甲基}-2-側氧基-2,3-二氫-1h-吲哚-5-基)甲基]-1,3-噻唑啶-2,4-二酮及egfr tyr激酶抑制劑之新穎結合物 | |
US8709420B2 (en) | Pharmaceutical combination of pazopanib and topotecan to treat neuroblastoma, osteosarcoma, and rhabdomyosarcoma in a human | |
JPWO2021108682A5 (ja) | ||
WO2016035023A1 (en) | Pharmaceutical combinations and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20141225 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150929 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151127 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20151127 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160419 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160516 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5945863 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |